Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C76H52O46.C9H13N |
| Molecular Weight | 1836.4047 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](N)CC1=CC=CC=C1.OC2=CC(=CC(O)=C2O)C(=O)OC3=CC(=CC(O)=C3O)C(=O)OC[C@H]4O[C@@H](OC(=O)C5=CC(O)=C(O)C(OC(=O)C6=CC(O)=C(O)C(O)=C6)=C5)[C@H](OC(=O)C7=CC(O)=C(O)C(OC(=O)C8=CC(O)=C(O)C(O)=C8)=C7)[C@@H](OC(=O)C9=CC(O)=C(O)C(OC(=O)C%10=CC(O)=C(O)C(O)=C%10)=C9)[C@@H]4OC(=O)C%11=CC(O)=C(O)C(OC(=O)C%12=CC(O)=C(O)C(O)=C%12)=C%11
InChI
InChIKey=LZHILFCCEFOKOG-VFRRKMCSSA-N
InChI=1S/C76H52O46.C9H13N/c77-32-1-22(2-33(78)53(32)92)67(103)113-47-16-27(11-42(87)58(47)97)66(102)112-21-52-63(119-72(108)28-12-43(88)59(98)48(17-28)114-68(104)23-3-34(79)54(93)35(80)4-23)64(120-73(109)29-13-44(89)60(99)49(18-29)115-69(105)24-5-36(81)55(94)37(82)6-24)65(121-74(110)30-14-45(90)61(100)50(19-30)116-70(106)25-7-38(83)56(95)39(84)8-25)76(118-52)122-75(111)31-15-46(91)62(101)51(20-31)117-71(107)26-9-40(85)57(96)41(86)10-26;1-8(10)7-9-5-3-2-4-6-9/h1-20,52,63-65,76-101H,21H2;2-6,8H,7,10H2,1H3/t52-,63-,64+,65-,76+;8-/m10/s1
CNS Activity
Approval Year
Doses
| Dose | Population | Adverse events |
|---|---|---|
0.15 mg/kg single, intravenous Dose: 0.15 mg/kg Route: intravenous Route: single Dose: 0.15 mg/kg Sources: |
unhealthy, 36.0 years (range: 20-58 years) n = 64 Health Status: unhealthy Condition: depression Age Group: 36.0 years (range: 20-58 years) Sex: M+F Population Size: 64 Sources: |
|
20 mg 2 times / day multiple, oral (max) Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Co-administed with:: chlorothiazide(1-2 g) Sources: |
unhealthy, 6-9 years n = 5 Health Status: unhealthy Condition: hyperactivity Age Group: 6-9 years Sex: M Population Size: 5 Sources: |
Disc. AE: Psychiatric disorders... AEs leading to discontinuation/dose reduction: Psychiatric disorders (2 patients) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Psychiatric disorders | 2 patients Disc. AE |
20 mg 2 times / day multiple, oral (max) Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Co-administed with:: chlorothiazide(1-2 g) Sources: |
unhealthy, 6-9 years n = 5 Health Status: unhealthy Condition: hyperactivity Age Group: 6-9 years Sex: M Population Size: 5 Sources: |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| inconclusive | weak (co-administration study) Comment: Lisdexamfetamine dimesylate (LDX), a prodrug of d-amphetamine, does not affect CYP2C19 activity in vitro. In a clinical trial a small C max reduction for omeprazole and its metabolite was observed, possibly reflecting an effect either on the activity of CYP2C19 or omeprazole absorption. |
|||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no | ||||
| yes |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1407-85-8
Created by
admin on Fri Dec 15 15:16:12 GMT 2023 , Edited by admin on Fri Dec 15 15:16:12 GMT 2023
|
PRIMARY | |||
|
m4226
Created by
admin on Fri Dec 15 15:16:12 GMT 2023 , Edited by admin on Fri Dec 15 15:16:12 GMT 2023
|
PRIMARY | Merck Index | ||
|
500Y9JV943
Created by
admin on Fri Dec 15 15:16:12 GMT 2023 , Edited by admin on Fri Dec 15 15:16:12 GMT 2023
|
PRIMARY | |||
|
72710632
Created by
admin on Fri Dec 15 15:16:12 GMT 2023 , Edited by admin on Fri Dec 15 15:16:12 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
